课题基金 / 基金详情

RILUTEK IN SLOWING PROGRESSION OF FTD

RILUTEK IN SLOWING PROGRESSION OF FTD
RILUTEK 减缓 FTD 的进展
批准号：
6117185
负责人：
Bruce Lee Miller
金额：
$3.89万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117185
关键词：
clinical research clinical trials dementia drug screening /evaluation electromyography human middle age (35-64) human old age (65+) human subject human therapy evaluation magnetic resonance imaging mental disorder chemotherapy neuropharmacologic agent psychological tests single photon emission computed tomography

项目摘要

项目成果

Bruce Lee Miller的其他基金

相似基金

相关文献

中文摘要
翻译
研究药物利鲁替克作为一种可能的治疗方法 额颞部痴呆。Rilutek目前已被FDA批准用于 肌萎缩侧索硬化症的治疗。FTD是一种皮质 常与肌萎缩侧索硬化症相关的退行性疾病。这个 ALS和FTD之间的关系尚不清楚，但需要进一步研究。 年龄在40岁到90岁之间的FTD患者， 将对他们的记忆力和思维能力进行测试，并进行核磁共振、SPECT和 进行肌电检查，并将在每次探视时抽血进行监测。
英文摘要
To investigate the medicine Rilutek as a possible treatment for Frontotemporal Dementia. Rilutek is currently approved by the FDA for treatment of amyotrophic Lateral Sclerosis. FTD is a cortical degenerative disorder that often occurs in association with ALS. The relationship between ALS and FTD is unexplained but needs further study. Patients with FTD between the ages of 40 and 90 years of age, Patients will have their memory and thinking tested, will have an MRI, SPECT and EMG performed and will have blood drawn at every visit to monitor ...
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RILUTEK IN SLOWING PROGRESSION OF FTD
UCLA ALZHEIMER'S DISEASE CENTER CORE GRANT
UCLA ALZHEIMER'S DISEASE CENTER CORE GRANT
UCLA ALZHEIMER'S DISEASE CENTER CORE GRANT
海外基金